Metabolomic profiling has pointed that ASS1 inhibition reduces the levels of oncogenic metabolite fumarate, resulting in impaired glycolytic phenotype and reduced CRC progression (Bateman et al., 2017). Here, ASS1 is linked to colorectal carcinoma.